Literature DB >> 25929861

Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance.

Xiaohui Wang, Xiaolei Li, Xiaoyu Fu, Miaomiao Bai, Xiang Li, Qian Mei, Jing Nie, Zhiqiang Wu, Weidong Han1.   

Abstract

Tumor recurrence followed by chemoresistance is a major cause of the poor survival rates for ovarian cancer. Despite advances in ovarian cancer chemotherapies and increased knowledge of the characteristics of ovarian cancer, chemoresistance is still an enormous clinical challenge. Current research suggests that ovarian cancer stem cells (OCSCs) might be involved in the occurrence of chemoresistance in ovarian cancer. In this review, we focus on the relationship of ovarian cancer stem cells with drug-resistant ovarian cancer phenotypes. We also discuss the current knowledge regarding ovarian cancer stem cell-based therapeutic strategies as attempts to overcome chemoresistance, the largest obstacle for successful treatment. Finally, we discuss methods for improving the treatment outcomes of ovarian cancer patients with chemoresistance.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25929861     DOI: 10.2174/138920371604150429151457

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  9 in total

1.  Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study.

Authors:  Dandan Yu; Ruth Holm; Mariusz Adam Goscinski; Claes G Trope; Jahn M Nesland; Zhenhe Suo
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

2.  Lumiflavin Reduces Cisplatin Resistance in Cancer Stem-Like Cells of OVCAR-3 Cell Line by Inducing Differentiation.

Authors:  Ruhui Yang; Bingjin Liu; Mingyue Yang; Feng Xu; Songquan Wu; Shufang Zhao
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

3.  The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.

Authors:  Shingo Tayama; Takeshi Motohara; Dashdemberel Narantuya; Chenyan Li; Koichi Fujimoto; Isao Sakaguchi; Hironori Tashiro; Hideyuki Saya; Osamu Nagano; Hidetaka Katabuchi
Journal:  Oncotarget       Date:  2017-07-04

4.  Overexpression of the cancer stem cell marker CD117 predicts poor prognosis in epithelial ovarian cancer patients: evidence from meta-analysis.

Authors:  Bikang Yang; Xuebing Yan; Liguo Liu; Chunyu Jiang; Shuping Hou
Journal:  Onco Targets Ther       Date:  2017-06-13       Impact factor: 4.147

5.  The novel ZIP4 regulation and its role in ovarian cancer.

Authors:  Qipeng Fan; Qingchun Cai; Pengfei Li; Wenyan Wang; Jing Wang; Emily Gerry; Tian-Li Wang; Ie-Ming Shih; Kenneth P Nephew; Yan Xu
Journal:  Oncotarget       Date:  2017-09-30

Review 6.  Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities.

Authors:  Carina Neitzel; Philipp Demuth; Simon Wittmann; Jörg Fahrer
Journal:  Cancers (Basel)       Date:  2020-06-29       Impact factor: 6.639

7.  Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells.

Authors:  Qianmei Zhou; Meina Ye; Yiyu Lu; Hui Zhang; Qilong Chen; Shuang Huang; Shibing Su
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

8.  The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells.

Authors:  Chiara Bellio; Celeste DiGloria; David R Spriggs; Rosemary Foster; Whitfield B Growdon; Bo R Rueda
Journal:  Cancers (Basel)       Date:  2019-10-29       Impact factor: 6.639

9.  Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer.

Authors:  Candace M Howard; Nadim Bou Zgheib; Stephen Bush; Timothy DeEulis; Antonio Cortese; Antonio Mollo; Seth T Lirette; Krista Denning; Jagan Valluri; Pier Paolo Claudio
Journal:  Transl Oncol       Date:  2020-08-28       Impact factor: 4.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.